华中首例HeartMate 3TM第三代人工心脏植入手术的成功，标志着我院在心衰治疗领域迈出了重要一步。我院2024年开展心脏移植手术101例，进入全球前十大心脏移植中心。为给心衰患者提供更多的治疗选择，2025年，我院在人工心脏领域迎来重大突破，从一月份至今，已开展14例人工心脏植入手术，迈入全国先进行列。
在麻醉监测中，脑电图衍生监测仪易受多种干扰。研究人员针对 HeartMate 3 TM 对肌电图指数（EMG）和双频谱指数（BIS）的影响展开研究。结果显示，HeartMate 3 TM 显著升高 EMG，但对 BIS 无显著影响。这有助于麻醉医生准确解读数据，提升麻醉管理质量。 在现代医疗 ...
研究人员回顾性查阅了 2012 年 1 月至 2021 年 12 月在本部门接受 HeartMate II（HMII）或 HeartMate 3（HM3）植入的成年患者的医疗记录。从机构数据库获取 LVAD 植入的临床过程和相关信息，包括人口统计学、临床数据、术前心律、术前和术后实验室数据以及不良事件发生 ...
原标题：华中首例！郑州市七院成功完成HeartMate3？“人工心脏”植入，58岁患者焕然“心”生2025年3月17日，郑州市第七人民医院（以下简称“郑州市七院”）心外科团队成功完成华中地区首例、全国第十例HeartMate ...
GlobalData on MSN5 个月
Abbott starts new trial to assess early use benefit of HeartMate 3Abbott has launched a “first-of-its-kind” trial to identify advanced heart failure patients who could potentially benefit ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Under the Agreement, Abbott will share insights from recent HeartMate 3™ trials and will support Cadrenal with: trial design, site identification, trial awareness, and HeartMate 3™ expertise.
Recently, Cardrenal announced a collaboration agreement with Abbott in which Abbott will assist Cadrenal with trial design, site identification, trial awareness, and HeartMate 3™ expertise.
Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3™ LVAD patients Cadrenal Therapeutics ...
GlobalData on MSN1 个月
Cadrenal and Abbott sign agreement for LVAD trial of tecarfarinThe company will receive Abbott’s insights from recent HeartMate 3 trials, including its support in designing the study, site ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈